Key result
Quantitative variant classification yields ~17% more actionable HCM cases by identifying disease-enriched regions.
Why the study?
International guidelines for variant interpretation in Mendelian disease prioritize controlling false positives over sensitivity and diagnostic yield, with limited data from diverse populations, motivating empirical calibration in inherited cardiomyopathies.
Case-Control
Yes
Answers are grounded in this paper and cite their sources.
May expand actionable HCM variant detection; leaves open prospective validation before clinical adoption.
Background International guidelines for variant interpretation in Mendelian disease set stringent criteria to report a variant as (likely) pathogenic, prioritising control of false positive rate over test sensitivity and diagnostic yield. Genetic testing is also more likely informative in individuals with well-characterised variants from extensively studied European-ancestry populations. Inherited cardiomyopathies are relatively common Mendelian diseases that allow empirical calibration and assessment of this framework. Results We compared rare variants in large hypertrophic cardiomyopathy (HCM) cohorts to reference populations to identify variant classes with high prior likelihoods of pathogenicity, as defined by etiological fraction (EF). Analysis of variant distribution identified regions in which variants are significantly enriched in cases and variant location was a better discriminator of pathogenicity than generic computational functional prediction algorithms. Non-truncating variant classes with an EF≥0.95, and therefore clinically actionable, were identified in 5 established HCM genes. Applying this approach leads to an estimated 14-20% increase in cases with actionable HCM variants. Conclusions When found in a patient confirmed to have disease, novel variants in some genes and regions are empirically shown to have a sufficiently high probability of pathogenicity to support a “likely pathogenic” classification, even without additional segregation or functional data. This could increase the yield of high confidence actionable variants, consistent with the framework and recommendations of current guidelines. The techniques outlined offer a consistent, unbiased and equitable approach to variant interpretation for Mendelian disease genetic testing. We propose adaptations to ACMG/AMP guidelines to incorporate such evidence in a quantitative and transparent manner.
No takes yet. Share an insight, caveat, or question.
Walsh et al. (2018) conducted a case-control in Hypertrophic cardiomyopathy. Rare non-truncating variants in MYH7 vs. Population controls (ExAC) was evaluated on Prevalence of rare non-truncating variants in MYH7 (OR 14.4, 95% CI 12.9-15.9, p=<0.0001). Quantitative approaches to variant classification using etiological fractions identified regions enriched for disease-associated variation, leading to an estimated 14-20% increase in cases with actionable HCM variants.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: